Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
I think we can call it ‘positive spin’ by an obviously confident CEO!
We can hyperventilate as much as we like over exact timings, down to the date of the RNS. Zoom out a bit and the linear progress is apparent!
Looking forward to CV results and the presentation. Not necessarily in that order ;)
You’re welcome to counter my post with known facts / RNS.
I *could* join the usual crowd and hyperventilate over the lack of news, and make it clear how disappointed I am at the delay.
Or just look at the facts and what has been delivered to date. Which of course includes what has *not* been delivered.
It’s all about context I suppose and how you see things panning out with our LFT. I don’t think there’ll be a problem with demand, that’s for certain. When we get CV results is anyone’s guess. But it’s potentially ‘soon’. Will it have the S&S we hope for and is as exquisite as has been suggested. I really hope so after many months of development!
Ndn - *perhaps* when working hand-in-glove with / to meet Govt requirements, there are certain things that may be RNS’d and certain things that may not?
Until there is an RNS to announce the poor / average / excellent S&S figures after full CV, we might all reasonably assume things are on track and we are close now. After all, it’s not as if we’ve been twiddling our thumbs since last summer. Plenty going on behind closed doors but of course, we’re all looking forward to THAT RNS. Thursday’s presentation was scheduled to happen regardless so we might as well all stop gurning about whether it’ll arrive by then or not.
... Avacta have, by month:
September ‘20 - Launched BAMS Assay to detect Covid for research purposes (in partnership with Adeptrix and Bruker).
November ‘20 - Announced it was working on two different sampling methods (saliva and AN) and have made significant progress with LFT development with BBI.
December ‘20 - Announce license agreement with Astrea Bioseparations, a division of Gamma Biosciences.
December ‘20 - Submitted CTA for AVA6000 with the intent to dose first patients later in the year.
January ‘21 - Entered agreement with POINT Biopharma providing an exclusive license to pre|CISION technology for use in the first radiopharmaceutical prodrug it develops.
February ‘21 - Further venture capital investment with AffyXell Therapeutics / Daewoong Pharmaceutical to develop novel mesenchymal stem cell therapies.
February ‘21 - Commercial partnership with Mologic / GAD to develop Avacta’s spike antigen test.
February ‘21 - CTA for AVA6000 approved, initial dosing intended for mid-2021, Covid permitting.
February ‘21 - Business Update for period ending December 31 2020 highlights strong cash position and ‘Significant Momentum in both Diagnostics and Therapeutics divisions’. ** Target mid-April as release date for preliminary results for FY ending 31 Dec 20**
“We are now confidently proceeding into full clinical validation to support a CE Mark, with a **potential** commercial launch for professional use **around the end of the first quarter** of this year.”
March ‘21 - Diagnostics Licensing deal with Biokit who are renowned as a Centre of Excellence with consolidated experience worldwide in research, development and manufacturing of assays and biomaterial solutions for IVD use.
March ‘21 - Announce the rapid antigen LFT detects different variants.
April ‘21 - Global distribution agreement with ABCAM for ELISA Affimer reagents.
What I read into the RNSs since last summer is continued progress. There are a lot of up front payments, royalties and milestone payments in all of the above. In several multi $Bn divisions. There is also a huge amount of confidence and investment on the part of the wider global pharmaceutical industry into our IP. Impressive stuff over the course of a few months.
What I also deduct from some RNS was a *potential* to launch the LFT *around the end* of Q1. That is very different to saying it WILL be launched by end of March / early April. As for the timing of this week’s update - that was telegraphed months ago in an RNS, long before the exact final stages of CV would’ve been known.
So when the derampers start wringing hands / accusing AS of missed deadlines / talking of failed tests... just read what has been put before us. I’m fully expecting a very positive AS to discuss excellent progress with CV, even if it hasn’t
materialised as quickly as everyone hoped. Assuming we don’t get an RNS before Thursday, of course.
I think he was referring to traders who sell then go on deramp in an attempt to get find a lower re-entry. At the expense of others. That would qualify as Scumbag Behaviour...
Plenty of people in need of a ‘lower re-entry’ judging by the chat today. And many in desperate need of a beer in an actual public house with actual people. Myself included. I might have mentioned it already...
Speaking of nerves, I’ve clearly got nothing better to do having taken this afternoon off for a 2 HOUR window in the pub for the first time since DECEMBER!
Never mind waiting for an RNS - I feel like a kid before Christmas...
Not having a go, Wyn.
I won’t elaborate any further - other than it’s a question of credibility here. And whether you’re in or out. I think the implication there is quite clear and I’m not trying to lecture anyone. I merely wished to point out certain individuals on here can be somewhat ‘opaque’, shall we say. All is fair, and all that ;)